
News|Videos|October 16, 2026
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
Advertisement
Advertisement
FDA’s discussion paper on generative AI for medical devices has opened a public comment period running through October 19, 2026, and the panelists on PharmTech AI Pulse Check argue that the industry’s response will matter well beyond device regulation. Richard Jaenisch, Florin Muraru, and Gourav Pandey walk through what they expect commenters to raise, and why pharma manufacturing, quality, and regulatory professionals, not just device makers, have a stake in how the conversation lands.
Related to this article

Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.

Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.

The PharmTech AI Pulse Check panel discusses why MHRA and FDA oversight of pharma AI continues past go-live, and who validates the regulators' own AI.

Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.

From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.

No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.

The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Advertisement
Advertisement

